Generic Name and Formulations:
Anidulafungin 50mg/vial, 100mg/vial; pwd for IV infusion after reconstitution and dilution; preservative-free; contains fructose and mannitol.
Indications for ERAXIS:
Candidemia. Esophageal candidiasis. Other Candida infections (intra-abdominal abscess, peritonitis).
Give by IV infusion; max rate 1.1mg/minute. Candidiasis, intra-abdominal abscess, peritonitis: 200mg on day 1, then 100mg/day for at least 14 days after last positive culture. Esophageal candidiasis: 100mg on day 1, then 50mg/day for at least 14 days and at least 7 days after symptom resolution.
≤16yrs: not established.
Follow-up if hepatic dysfunction develops. Discontinue and treat appropriately if anaphylactic reactions occur. Pregnancy: avoid. Nursing mothers.
Glucan synthesis inhibitor (echinocandin).
Hypokalemia, GI upset, pyrexia, insomnia, anemia, headache, dyspepsia; hepatic effects, infusion reactions, anaphylactic reactions.
Fecal, renal (minor).
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Differences in Efficacy and Tolerability of ADHD Medications Across Age Groups
- Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia
- Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
- Comorbid Narcolepsy and Schizophrenia in Adolescents
- Ketamine in Electroconvulsive Therapy Accelerates Antidepressive Effects
- Incorporating Guidelines Into Clinical Practice: An Interview With Gary L. LeRoy, MD
- Disaster Preparedness 101: Physician Resources for Patients
- Adverse Events Caused by Once-Monthly Aripiprazole Are Time Limited
- Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations
- Selective Serotonin Reuptake Inhibitors May Increase Risk for Suboptimal Fetal Growth